Der Internist

, Volume 49, Issue 2, pp 170–177 | Cite as

Prävention von Erkrankungen des Respirationstrakts

Schwerpunkt: Prävention in der Inneren Medizin


Die Möglichkeiten der pulmonalen oder bronchialen Schädigungen sind mannigfaltig und übertreffen an Zahl andere, in diesem Heft bearbeitete Organsysteme. Durch diese Vielzahl der Erkrankungen, die zumindest partiell auf exogene Schädigungen zurückzuführen sind, ergeben sich aber auch mannigfaltige Ansätze zur Prävention. Die vorliegende Übersicht erhebt keinen Anspruch auf Vollständigkeit. Sie soll aber die Möglichkeiten verdeutlichen, die in der Prävention pulmonaler Erkrankungen bestehen. Sie soll aber auch aufzeigen, dass eine wirksame Primär-, und gelegentlich Sekundär- und Tertiärprävention in der Lungenheilkunde immer noch unzureichend oder gar nicht genutzt werden. Vor dem Hintergrund, dass präventive Maßnahmen auch in der Pneumologie individuell, aber auch aus Sicht der Gesundheitsökonomie, wesentlich erfolgreicher sind als Maßnahmen zur Kuration, sollen verschiedene Möglichkeiten erfolgreicher Prävention aufgezeigt werden. Darüber hinaus wird der große Bedarf an Studien zur Wirksamkeit präventiver Strategien erläutert.


Lunge Prävention Rauchen Allergien Schadstoffe 

Prevention of respiratory tract diseases


There are multiple possibilities for pulmonary or bronchial damage and their number exceeds that for the other organ systems dealt with in this issue. This multiplicity of diseases which are at least in part attributable to exogenous damage gives rise to manifold approaches to prevention. This overview does not claim to be complete. It is however intended to clarify the possibilities that exist for the prevention of pulmonary diseases. In addition, it intends to show that effective primary and occasionally secondary and tertiary prevention is inadequately utilized in pulmonology or not even used at all. Against the background that individual preventive measures in pulmonology are considerably more successful than curative measures, also from a health economics point of view, various options for successful prevention are described. The great need for studies on the effectiveness of preventive strategies is also addressed.


Lung Prevention Smoking Allergies Harmful substances 



Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.


  1. 1.
    Aristegui J, Bernaola E, Pocheville I et al. (2007) Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine. Eur J Clin Microbiol Infect Dis 26: 303–310PubMedCrossRefGoogle Scholar
  2. 2.
    Barone-Adesi F, Vizzini L, Merletti F, Richiardi L (2006) Short-term effects of Italian smoking regulation on rates of hospital admission for acute myocardial infarction. Eur Heart J 27: 2468–2472PubMedCrossRefGoogle Scholar
  3. 3.
    Braun-Fahrlander C (2003) Environmental exposure to endotoxin and other microbial products and the decreased risk of childhood atopy: evaluating developments since April 2002. Curr Opin Allergy Clin Immunol 3: 325–329PubMedCrossRefGoogle Scholar
  4. 4.
    Calverley PM, Anderson JA, Celli B et al. (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356: 775–789PubMedCrossRefGoogle Scholar
  5. 5.
    Casaburi R, Kukafka D, Cooper CB et al. (2005) Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 127: 809–817PubMedCrossRefGoogle Scholar
  6. 6.
    Casaburi R, Mahler DA, Jones PW et al. (2002) A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19: 217–224PubMedCrossRefGoogle Scholar
  7. 7.
    Chandran A, Watt JP, Santosham M (2005) Prevention of Haemophilus influenzae type b disease: past success and future challenges. Expert Rev Vaccines 4: 819–827PubMedCrossRefGoogle Scholar
  8. 8.
    Churchyard GJ, Scano F, Grant AD, Chaisson RE (2007) Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis (Suppl 1) 196: S52–S62Google Scholar
  9. 9.
    Ciofi Degli Atti ML, Filia A, Massari M et al. (2006) Assessment of measles incidence, measles-related complications and hospitalisations during an outbreak in a southern Italian region. Vaccine 24: 1332–1338CrossRefGoogle Scholar
  10. 10.
    Claes C, Schulenburg JM Graf von der (2003) Cost effectiveness of pneumococcal vaccination for infants and children with the conjugate vaccine PnC-7 in Germany. Pharmacoeconomics 21: 587–600PubMedCrossRefGoogle Scholar
  11. 11.
    Doll R, Peto R, Wheatley K et al. (1994) Mortality in relation to smoking: 40 years‘ observations on male British doctors. BMJ 309: 901–911PubMedGoogle Scholar
  12. 12.
    Ellerbeck EF, Ahluwalia JS, Jolicoeur DG et al. (2001) Direct observation of smoking cessation activities in primary care practice. J Fam Pract 50: 688–693PubMedGoogle Scholar
  13. 13.
    Filia A, Brenna A, Pana A et al. (2007) Health burden and economic impact of measles-related hospitalizations in Italy in 2002–2003. BMC Public Health 7: 169PubMedCrossRefGoogle Scholar
  14. 14.
    Fisman DN, Abrutyn E, Spaude KA et al. (2006) Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis 42: 1093–1101PubMedCrossRefGoogle Scholar
  15. 15.
    Fitzpatrick TM, Blair EA (2000) Upper airway complications of smoking. Clin Chest Med 21: 147–157, xPubMedCrossRefGoogle Scholar
  16. 16.
    Garwood CL, Potts LA (2007) Emerging pharmacotherapies for smoking cessation. Am J Health Syst Pharm 64: 1693–1698PubMedCrossRefGoogle Scholar
  17. 17.
    Grijalva CG, Nuorti JP, Arbogast PG et al. (2007) Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369: 1179–1186PubMedCrossRefGoogle Scholar
  18. 18.
    Heinrich J, Slama R (2007) Fine particles, a major threat to children. Int J Hyg Environ Health 210: 617–622PubMedCrossRefGoogle Scholar
  19. 19.
    Horsburgh CR (2004) Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 350: 2060–2067PubMedCrossRefGoogle Scholar
  20. 20.
    Hurt RD, Ebbert JO (2002) Preventing lung cancer by stopping smoking. Clin Chest Med 23: 27–36, viiPubMedCrossRefGoogle Scholar
  21. 21.
    Hurt RD, Sachs DP, Glover ED et al. (1997) A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337: 1195–1202PubMedCrossRefGoogle Scholar
  22. 22.
    Joad JP (2000) Smoking and pediatric respiratory health. Clin Chest Med 21: 37–46, vii–viiiPubMedCrossRefGoogle Scholar
  23. 23.
    Johnstone J, Marrie TJ, Eurich DT, Majumdar SR (2007) Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med 167: 1938–1943PubMedCrossRefGoogle Scholar
  24. 24.
    Kumra V, Markoff BA (2000) Who’s smoking now? The epidemiology of tobacco use in the United States and abroad. Clin Chest Med 21: 1–9, viiPubMedCrossRefGoogle Scholar
  25. 25.
    Lacasse Y, Goldstein R, Lasserson TJ, Martin S (2006) Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 4: CD003793PubMedGoogle Scholar
  26. 26.
    MacNee W, Donaldson K (2000) Exacerbations of COPD: environmental mechanisms. Chest 117: 390S–397SPubMedCrossRefGoogle Scholar
  27. 27.
    Martin C (2006) Tuberculosis vaccines: past, present and future. Curr Opin Pulm Med 12: 186–191PubMedCrossRefGoogle Scholar
  28. 28.
    Niggemann B, Jacobsen L, Dreborg S et al. (2006) Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 61: 855–859PubMedCrossRefGoogle Scholar
  29. 29.
    O’Donnell DE, Sciurba F, Celli B et al. (2006) Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 130: 647–656CrossRefGoogle Scholar
  30. 30.
    Percival J (2007) Smoking: tackling the silent epidemic. J Fam Health Care 17: 109–110PubMedGoogle Scholar
  31. 31.
    Potts LA, Garwood CL (2007) Varenicline: the newest agent for smoking cessation. Am J Health Syst Pharm 64: 1381–1384PubMedCrossRefGoogle Scholar
  32. 32.
    Rose MA, Schubert R, Kujumdshiev S et al. (2006) Immunoglobulins and immunogenicity of pneumococcal vaccination in preschool asthma. Int J Clin Pract 60: 1425–1431PubMedCrossRefGoogle Scholar
  33. 33.
    Silagy C, Lancaster T, Stead L et al. (2004) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 3: CD000146PubMedGoogle Scholar
  34. 34.
    Tanoue LT (2000) Cigarette smoking and women’s respiratory health. Clin Chest Med 21: 47–65PubMedCrossRefGoogle Scholar
  35. 35.
    Vincken W, Noord JA van, Greefhorst AP et al. (2002) Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur Respir J 19: 209–216PubMedCrossRefGoogle Scholar
  36. 36.
    Wedzicha JA, Calverley PM, Seemungal TA et al. (2007) The prevention of COPD exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med [Epub ahead of print]Google Scholar
  37. 37.
    Wills-Karp M, Brandt D, Morrow AL (2004) Understanding the origin of asthma and its relationship to breastfeeding. Adv Exp Med Biol 554: 171–191PubMedGoogle Scholar
  38. 38.
    Wisloff T, Abrahamsen TG, Bergsaker MA et al. (2006) Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program. Vaccine 24: 5690–5699PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag 2008

Authors and Affiliations

  1. 1.Abteilung für Pneumologie, Medizinische Klinik und PoliklinikUniversitätsklinikum RostockRostockDeutschland

Personalised recommendations